Tyra Biosciences appoints drug developer to board

Tyra Biosciences appoints drug developer to board

Tyra Biosciences Inc, a developer of precision medicines that target large opportunities in fibroblast growth factor receptor (FGFR) biology, has appointed Adele Gulfo to its board of directors. Ms Gulfo brings almost three decades of expertise in product development and commercialisation, including Pfizer’s Lipitor, AstraZeneca’s Crestor and Orgovyx for prostate cancer. The appointment comes as Tyra Biosciences plans late-stage development of its lead product TYRA-300 in non-muscle invasive bladder cancer. Most recently, Ms Gulfo was chief executive officer, biopharma commercial unit, at Sumitomo Pharma America and previously was chief commercial and business development officer at Sumitovant Biopharma. Earlier she held executive positions at Pfizer and AstraZeneca.

Tyra Biosciences announced the appointment on 29 January 2025.